As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar ...

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

President Trump hailed his deal with pharma companies on GLP-1 drug pricing. The question is how big of a difference the deal ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

The rise of GLP-1 weight loss drugs has been a game-changer for the grocery sector, and the dairy segment appears ...